<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764907</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000613220</org_study_id>
    <secondary_id>MOTOL-ALL-IC-BFM-2002</secondary_id>
    <secondary_id>EU-20871</secondary_id>
    <nct_id>NCT00764907</nct_id>
  </id_info>
  <brief_title>Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may&#xD;
      replace the patient's immune cells and help destroy any remaining cancer cells&#xD;
      (graft-versus-tumor effect). Giving combination chemotherapy before the transplant helps stop&#xD;
      the growth of cancer cells and stop the patient's immune system from rejecting the donor's&#xD;
      stem cells. It is not yet known which combination chemotherapy regimen is more effective in&#xD;
      treating young patients with acute lymphoblastic leukemia.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying different risk-adjusted combination&#xD;
      chemotherapy regimens in treating young patients with acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To test in a randomized way the type and intensity of reintensification therapy for&#xD;
           pediatric patients with acute lymphoblastic leukemia in each risk group: standard-risk&#xD;
           (SR), intermediate-risk (IR), and high-risk (HR) group.&#xD;
&#xD;
        -  To compare two shorter elements of reintensification (protocol III x 2 courses) to one&#xD;
           (protocol II x 1 course) in terms of effectiveness when cumulative dose of most drugs&#xD;
           are the same in both regimen in patients in the standard-risk group.&#xD;
&#xD;
        -  To determine if the increased risk of failure in patients in the intermediate-risk group&#xD;
           can be curtailed by a third reintensification element (protocol III x 3 courses vs&#xD;
           protocol II x 1 course).&#xD;
&#xD;
        -  To determine if the three reintensification elements (protocol III x 3 courses) achieve&#xD;
           the same or better results in high-risk group patients, as compared with current applied&#xD;
           HR approach in Berlin-Frankfurt-Münster Group (BFM) or Italian Association of Pediatric&#xD;
           Hematology and Oncology (AIEOP).&#xD;
&#xD;
      OUTLINE: This is a partially randomized, multicenter study. Patients are stratified according&#xD;
      to risk group (standard risk [SR] vs intermediate risk [IR] vs high risk [HR]). Patients are&#xD;
      randomized in reinduction part of the treatment.&#xD;
&#xD;
        -  Induction therapy:&#xD;
&#xD;
             -  Protocol I' (SR B-cell precursor [BCP] ALL ): Patients receive methotrexate&#xD;
                intrathecally (IT) on days 1, 12, and 33 (and possibly on days 18 and 27);&#xD;
                prednisone or prednisolone orally or IV on days 1-28 followed by a taper;&#xD;
                vincristine sulfate IV on days 1, 8, 15, 22, and 29; daunorubicin hydrochloride IV&#xD;
                over 1 hour on days 8 and 15; and asparaginase IV over 1 hour on days 12, 15, 18,&#xD;
                21, 24, 27, 30, and 33. Patients then receive cyclophosphamide IV over 1 hour on&#xD;
                days 36 and 64; oral mercaptopurine once daily on days 36-63; cytarabine IV&#xD;
                continuously on days 38-41, 45-48, 52-55, and 59-62; and methotrexate IT on days 45&#xD;
                and 59.&#xD;
&#xD;
             -  Protocol I (SR T-cell ALL, IR, or HR): Patients receive therapy as in Protocol I'&#xD;
                except that they also receive daunorubicin hydrochloride on days 22 and 29.&#xD;
&#xD;
      Approximately 2 weeks after completion of induction therapy, patients proceed to&#xD;
      consolidation therapy.&#xD;
&#xD;
        -  Consolidation: Patients who have achieved complete cytomorphologic remission proceed to&#xD;
           protocol mM or protocol M. Patients in HR group proceed to 3-block consolidation&#xD;
           regimen.&#xD;
&#xD;
             -  Protocol mM (BCP-ALL) (SR or IR): Patients receive oral mercaptopurine once daily&#xD;
                on days 1-56; medium-dose methotrexate IV over 24 hours and methotrexate IT on days&#xD;
                8, 22, 36, and 50; and leucovorin calcium IV every 6 hours on days 9, 23, 37, and&#xD;
                51.&#xD;
&#xD;
             -  Protocol M (T-cell ALL) (SR or IR): Patients receive mercaptopurine, methotrexate&#xD;
                IT, and leucovorin calcium as in protocol mM, and they also receive high-dose (HD)&#xD;
                methotrexate IV over 24 hours on days 8, 22, 36, and 50.&#xD;
&#xD;
             -  3-block consolidation regimen (HR): Patients receive 3 regimen blocks with 2 weeks&#xD;
                between blocks. Treatment continues in the absence of unacceptable toxicity.&#xD;
&#xD;
                  -  Block HR-1': Patients receive dexamethasone orally or IV 3 times daily on days&#xD;
                     1-5; vincristine sulfate IV on days 1-6; HD methotrexate IV over 24 hours on&#xD;
                     day 1; leucovorin calcium IV every 6 hours, beginning 42 hours after the start&#xD;
                     of HD methotrexate, for 3 doses; cyclophosphamide IV over 1 hour, every 12&#xD;
                     hours, on days 2-4; HD cytarabine IV over 3 hours, every 12 hours, on day 5 (2&#xD;
                     doses); asparaginase IV over 2 hours on days 6 and 11; and triple intrathecal&#xD;
                     therapy (TIT) comprising methotrexate, cytarabine, and prednisone, 3 times on&#xD;
                     day 1.&#xD;
&#xD;
                  -  Block HR-2': Patients receive dexamethasone, HD methotrexate, leucovorin&#xD;
                     calcium, and asparaginase as in block HR-1'. Patients receive TIT once on day&#xD;
                     1 (CNS-negative patients) or twice on days 1 and 5 (CNS-positive patients).&#xD;
                     Patients also receive vindesine IV on days 1 and 6; ifosfamide IV over 1 hour,&#xD;
                     every 12 hours, on days 2-4; and daunorubicin hydrochloride IV over 24 hours&#xD;
                     on day 5.&#xD;
&#xD;
                  -  Block HR-3': Patients receive dexamethasone and asparaginase as in block&#xD;
                     HR-1'; TIT 3 times on day 5; HD cytarabine IV over 3 hours, every 12 hours, on&#xD;
                     days 1 and 2; and etoposide IV over 1 hour, every 12 hours, on days 3-5.&#xD;
&#xD;
      Approximately 2 weeks after completion of consolidation therapy, patients proceed to&#xD;
      reinduction therapy.&#xD;
&#xD;
        -  Reinduction (randomized): Patients in continuous complete remission proceed to protocol&#xD;
           II or III. Patients from SR and IR group are randomized to arms I and II; patients from&#xD;
           HR group are randomized to arms II and III.&#xD;
&#xD;
             -  Arm I (protocol II x 1 course) (SR-1 or IR-1): Patients receive dexamethasone&#xD;
                orally or IV on days 1-21 followed by a taper; vincristine sulfate IV and&#xD;
                doxorubicin hydrochloride IV over 1 hour on days 8, 15, 22, and 29; asparaginase IV&#xD;
                over 1 hour on days 8, 11, 15, and 18; and methotrexate IT on days 1 and 18.&#xD;
                Patients then receive cyclophosphamide IV over 1 hour on day 36; oral thioguanine&#xD;
                once daily on days 36-49; cytarabine IV continuously on days 38-41 and 45-48; and&#xD;
                methotrexate IT on days 38 and 45.&#xD;
&#xD;
             -  Arm II (protocol III x 2 or 3 courses and interim maintenance therapy [IMT]) (SR-2,&#xD;
                IR-2, or HR-1): Patients receive dexamethasone orally or IV three times daily on&#xD;
                days 1-14 followed by a taper; vincristine sulfate IV and doxorubicin hydrochloride&#xD;
                IV over 1 hour on days 1 and 8; and asparaginase IV over 1 hour on days 1, 4, 8,&#xD;
                and 11. Patients then receive cyclophosphamide IV over 1 hour on day 15; oral&#xD;
                thioguanine once daily on days 15-28; cytarabine IV continuously on days 17-20 and&#xD;
                24-27; and methotrexate IT on days 17 and 21 (and day 1 if there is initial CNS&#xD;
                involvement). Approximately 1 week after completion of protocol III (course 1),&#xD;
                patients receive IMT for 10 weeks (SR group) or 4 weeks (IR and HR groups) as&#xD;
                described below. Approximately 1 week after completion of IMT, patients receive&#xD;
                protocol III as above (course 2). Approximately 1 week after completion of protocol&#xD;
                III (course 2), patients in IR and HR group receive IMT for another 4 weeks&#xD;
                followed by another course of protocol III (course 3) 1 week later.&#xD;
&#xD;
                  -  IMT: Patients receive oral methotrexate once weekly and oral mercaptopurine&#xD;
                     daily.&#xD;
&#xD;
             -  Arm III (HR-2): Patients receive 1 of the following regimens according to local&#xD;
                practices:&#xD;
&#xD;
                  -  Regimen HR-2A: Patients receive protocol II as in arm I, rest 1 week and&#xD;
                     receive IMT for 4 weeks. Approximately 1 week later, patients receive another&#xD;
                     course of protocol II.&#xD;
&#xD;
                  -  Regimen HR-2B: Patients receive treatment as in 3-block consolidation regimen&#xD;
                     with 3 weeks between each block. Approximately 3 weeks later, patients receive&#xD;
                     protocol II as in arm I.&#xD;
&#xD;
             -  Cranial radiotherapy (CRT) during reinduction: CNS positive patients (CNS status 3)&#xD;
                receive CRT after completion of protocol II (SR, IR, HR-2B) or during the first&#xD;
                1.5-2.5 weeks of IMT (SR, IR, HR-2A). SR and IR patients with T-cell ALL and HR&#xD;
                patients receive prophylactic CRT at these same time periods.&#xD;
&#xD;
      Beginning 2 weeks after completion of reinduction (some patients in HR group also undergo&#xD;
      allogeneic stem cell transplantation, as described below), patients proceed to maintenance&#xD;
      therapy.&#xD;
&#xD;
        -  Maintenance therapy (MT): Patients receive oral mercaptopurine once daily and&#xD;
           methotrexate IV once weekly. Each patient subgroup (except HR patients undergoing&#xD;
           transplantation) receives MT for a period that brings the total weeks of treatment to&#xD;
           104 weeks, as follows:&#xD;
&#xD;
             -  SR: Patients receive MT for 74 weeks (SR-1) or 61 weeks (SR-2).&#xD;
&#xD;
             -  IR: Patients receive MT for 74 weeks (IR-1) or 57 weeks (IR-2).&#xD;
&#xD;
             -  HR: Patients receive MT for 58 weeks (HR-1), 62 weeks (HR-2A), or 63 weeks (HR-2B).&#xD;
&#xD;
      Patients with BCP-ALL and in group SR-1 or IR-1 also receive methotrexate IT once in weeks 4,&#xD;
      8, 12, and 16 of MT. Patients with BCP-ALL and in group SR-2 receive methotrexate IT in weeks&#xD;
      4 and 8 of MT.&#xD;
&#xD;
        -  Allogeneic stem cell transplantation (ASCT): Some patients in HR group may undergo ASCT&#xD;
           (usually bone marrow, but may be peripheral blood or umbilical cord stem cells), (at the&#xD;
           time of reinduction therapy) beginning 3-4 weeks after the completion of second protocol&#xD;
           III (HR-1), the first protocol II (HR-2A), or completion of the 3-block consolidation&#xD;
           regimen (HR-2B).&#xD;
&#xD;
             -  Under 2 years old: Patients receive oral busulfan every 6 hours on days -8 to -5,&#xD;
                etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on days -3&#xD;
                and -2, and then undergo ASCT on day 0.&#xD;
&#xD;
             -  At least 2 years old: Patients undergo total body irradiation twice daily on days&#xD;
                -6 to -4 and receive etoposide IV over 4 hours on day -3, and then undergo ASCT on&#xD;
                day 0. Fractionated local radiotherapy, if required, is administered on days -14 to&#xD;
                -7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Anticipated">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During reinduction, patients receive 1 course of protocol II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV or orally during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given orally during reinduction</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given orally during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given intrathecally during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>Given orally during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vindesine</intervention_name>
    <description>Given IV during reinduction</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytologically proven acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
          -  No relapse of a previously unrecognized ALL&#xD;
&#xD;
          -  Patients must meet one of the following risk criteria:&#xD;
&#xD;
               -  Standard-risk (SR) group meeting all of the following criteria:&#xD;
&#xD;
                    -  Blasts &lt; 1,000/μL in peripheral blood (PB) on day 8&#xD;
&#xD;
                    -  Aged 1 to &lt; 6 years&#xD;
&#xD;
                    -  Initial WBC &lt; 20,000/μL&#xD;
&#xD;
                    -  M1 (5%) or M2 (≥ 5% to &lt; 25%) blasts in bone marrow on day 15&#xD;
&#xD;
                    -  M1 marrow on day 33&#xD;
&#xD;
               -  Intermediate-risk (IR) group meeting all of the following criteria:&#xD;
&#xD;
                    -  Aged &lt; 1 or ≥ 6 years and/or WBC ≥ 20,000/μL&#xD;
&#xD;
                    -  Blasts &lt; 1,000/μL in PB on day 8&#xD;
&#xD;
                    -  M1 or M2 marrow on day 15&#xD;
&#xD;
                    -  M3 (≥ 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and&#xD;
                       M1 marrow on day 33&#xD;
&#xD;
               -  High-risk (HR) group meeting ≥ 1 of the following criteria:&#xD;
&#xD;
                    -  Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)&#xD;
&#xD;
                    -  Blasts ≥ 1,000/μL in PB on day 8&#xD;
&#xD;
                    -  M2 or M3 marrow on day 33&#xD;
&#xD;
                    -  Translocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or&#xD;
                       t(4;11) [MLL/AF4+]&#xD;
&#xD;
          -  No secondary ALL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No Down syndrome&#xD;
&#xD;
          -  No other major disease that prohibits study treatment (e.g., severe congenital heart&#xD;
             disease)&#xD;
&#xD;
          -  Not requiring significant therapy modification owing to study therapy-associated&#xD;
             complications&#xD;
&#xD;
          -  No complications due to other interventions&#xD;
&#xD;
          -  No one with missing data that are needed for the differential diagnosis, or for&#xD;
             selection of the proper therapy arm&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No steroids or cytostatic drugs within four weeks prior to start of study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Stary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Motol</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Stary, MD</last_name>
      <phone>420-2-2443-6401</phone>
      <email>jan.stary@lfmotol.cuni.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>July 7, 2009</last_update_submitted>
  <last_update_submitted_qc>July 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2009</last_update_posted>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

